The presence of NF-κB and IFN signatures in ccRCC has exciting therapeutic implications, especially as the advanced form of this disease is currently incurable, and as prevalent small-molecule options – centered largely on neutralizing angiogenesis and nutrient-sensing nodes – only delay progression of disease. Here, NFKB1 is linked to nonpapillary renal cell carcinoma.